Evidence map›Paper›PMID 39605649›Full record

ArticlebioRxiv : the preprint server for biology2024

Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies.

Benjamin Diamond, Dhanvantri Chahar, Michael D Jain, Alexandra M Poos, Michael Durante, Bachisio Ziccheddu, Marcella Kaddoura, Marios Papadimitriou, Kylee Maclachlan, Tomas Jelinek and 14 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Benjamin DiamondMyeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.ORCID 0000-0002-8638-9365
Dhanvantri ChaharLymphoma Service, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Michael D JainLymphoma Service, Moffitt Cancer Center, Tampa, FL, USA.
Alexandra M PoosHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Michael DuranteMyeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Bachisio ZicchedduMyeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Marcella KaddouraMyeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Marios PapadimitriouMyeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Kylee MaclachlanMyeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tomas JelinekDepartment of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Czech Republic.
Faith DaviesMyeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York, NY, USA.
Nicholas B FiguraDepartment of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Gareth MorganMyeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York, NY, USA.
Elias MaiHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Katja C WeiselDepartment of Oncology, Hematology and Blood and Marrow Transplant, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Roland FenkDepartment of Hematology, Oncology and Clinical Immunology, University-Hospital Duesseldorf, Duesseldorf, Germany.
Marc S RaabHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Saad UsmaniMyeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ola LandgrenMyeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Frederick L LockeLymphoma Service, Moffitt Cancer Center, Tampa, FL, USA.
Hartmut GoldschmidtHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Jonathan H SchatzLymphoma Service, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Niels WeinholdHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Francesco MauraMyeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Stephen D. Nimer · 2019 to 2026
$24.1M
UM Calabresi Clinical Oncology Research Career Development AwardK12CA226330 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Alan Pollack · 2018 to 2026
$5.1M
NCI NIH HHS K12 CA226330NCI NIH HHS P30 CA240139
6 · The paper itself

Abstract

Ionizing radiotherapy (RT) is a widely used palliative and curative treatment strategy for malignancies. In solid tumors, RT-induced double strand breaks lead to the accumulation of indels, and their repair by non-homologous end-joining has been linked to the ID8 mutational signature in resistant cells. However, the extent of RT-induced DNA damage in hematologic malignancies and its impact on their evolution and interplay with commonly used chemotherapies has not yet been explored. Here, we interrogated 580 whole genome sequencing (WGS) from patients with large B-cell lymphoma, multiple myeloma, and myeloid neoplasms and identified ID8 only in relapsed disease. Yet, it was detected after exposure to both RT and mutagenic chemotherapy (i.e., platinum). Using WGS of single-cell colonies derived from treated lymphoma cells, we revealed a dose-response relationship between RT and platinum and ID8. Finally, using ID8 as a genomic barcode we demonstrate that a single RT-resistant cell may seed systemic relapse.

Indexed as

Diffuse Large B-cell LymphomaDNA damageMultiple MyelomaMutational SignaturesRadiationRadiotherapyWhole Genome Sequencing

Identifiers

PMID39605649
PMCPMC11601314

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.